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been identified as a cause of autosomal
dominant cerebellar ataxia.6 Immuno-
histochemical studies on cerebellar tis-
sue from an affected member of a family
with PKCc missense mutation showed
reduced staining for both PKCc and
ataxin 1 in Purkinje cells, suggesting
that there may be a common pathway
for PKCc and polyglutamine-related
neurodegeneration.6 This hypothesis is
also supported by the fact that in
spinocerebellar ataxia type 1 (SCA1)
transgenic mice, PKCc degradation
occurs before the onset of ataxia, sug-
gesting that the loss of this protein is
important for the Purkinje cell dysfunc-
tion observed in SCA1 patients.5 A link
between paraneoplastic and genetic
cerebellar ataxia is also illustrated by
voltage-gated calcium channel antibo-
dies (VGCC-Ab). VGCC-Ab, especially
those directed against the P/Q type
VGCC, are mainly associated with
Lambert–Eaton myasthenic syndromes
(LEMS),7 which are paraneoplastic in
.70% of the patients. Studies have
shown that the frequency of cerebellar
ataxia in patients with LEMS is higher
than that expected by chance, and that
LEMS with ataxia is usually associated
with cancer.8 VGCC-Ab against the P/Q
type have also been found in patients
with small cell lung cancer and PCA
without LEMS,9 suggesting that VGCC
could be associated with some cases of
PCA. P/Q type VGCCs are highly
expressed in the cerebellum, and gene
mutations coding for VGCCs have been
identified as a cause of autosomal
dominant cerebellar ataxia (SCA6).10
These data showed that PKCc and P/Q
type VGCCs could be associated with
cerebellar ataxia as both paraneoplastic
antigen and key mutated protein. From
these observations, we can draw two
conclusions: although PCA-associated
antibodies have not definitively been
proven to be pathogenic, they can be
used as diagnosis markers to classify
subtypes of cerebellar ataxia; although
some paraneoplastic antibodies can be
observed in only one or two patients,
identification of the antigens may have
important implications in the identifica-
tion of key proteins, which could be
associated with the neuronal injury of
patients with sporadic or genetic cere-
bellar ataxia.
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Physiological abnormalities are a worthwhile target
D
elayed cerebral ischaemia (DCI)
affects more than one quarter of
patients between 3 and 14 days
after the onset of their aneurysmal
subarachnoid haemorrhage, and
accounts for about one third of patients
who are dead or dependent as a result of
the haemorrhage. Despite the impor-
tance of DCI, little can be done to
prevent it: only calcium antagonists are
supported by good evidence, and the
effectiveness of nimodipine is modest
(20 patients need to be treated to
prevent one poor outcome).1 Future
hope is offered only by the window of
opportunity between subarachnoid hae-
morrhage and DCI onset, and sufficient
clinical research interest in finding
further interventions for the prophylaxis
and treatment of DCI.
In trying to discover whether poten-
tially modifiable physiological abnorm-
alities are a worthwhile target for
intervention to prevent DCI, the paper
by Naidech et al2 (p 1340) explores the
association between cerebral infarcts on
computed tomograms of the brain after
aneurysmal subarachnoid haemorrhage
and a physiological derangement score
at the time of admission to hospital
(based on a patient’s oxygenation,
acidosis, glycaemic control and blood
pressure). In contrast with the study
that originally derived the physiological
derangement score,3 the present study is
small and retrospective, with an over-
representation of subarachnoid haemor-
rhages that were severe or located in the
posterior circulation. Furthermore, the
study used a radiological marker of DCI
rather than clinically important out-
come data after discharge from hospital.
The authors strove to identify cerebral
infarcts due to vasospasm, but multi-
variate analysis found only clinical
severity of subarachnoid haemorrhage
and physiological derangement score to
be associated with cerebral infarcts.
However, the size of the study sample
precluded the inclusion of other known
determinants of DCI (such as prolonged
duration of unconsciousness at onset of
subarachnoid haemorrhage) and its
design did not allow an analysis of the
influence of endovascular or surgical
treatment.
The study by Naidech et al2 provokes
many questions. Might alternative scor-
ing systems using additional variables
be better at predicting poor clinical
outcome?4 Might altered physiology
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simply be an epiphenomenon reflecting
subarachnoid haemorrhage severity?
Could physiological derangement at
later stages of admission to hospital be
even more influential (as is the case for
hypomagnesaemia5)? As vasospasm is
neither necessary nor sufficient to
account for DCI, retaining the focus on
determinants of poor outcome and DCI is
likely to be most beneficial for patients.
There are many potential targets for
prevention of DCI, including endothelial
activation, cortical spreading depression,
excitotoxicity mediated by raised intracel-
lular calcium, apoptosis, nitric oxide
depletion, free radical formation and
mitochondrial dysfunction, many of
which may be influenced by the physio-
logical abnormalities in the patient.
For now, the correction of some
physiological abnormalities (such as
hypoxia, hypotension and hyperglycae-
mia) after aneurysmal subarachnoid
haemorrhage seems to be clinical com-
mon sense, not least to try and mitigate
the major effect on cardiorespiratory
function after subarachnoid haemor-
rhage4. This approach further reinforces
the importance of multidisciplinary
team management, including critical
care.6 To investigate whether DCI could
be prevented by more aggressive treat-
ment of physiological derangements
would require large randomised con-
trolled trials, in addition to the ongoing
clinical trials of magnesium, simvastatin
and clazosentan.4
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